Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents.

Methods in molecular biology (Clifton, N.J.) - 1 Jan 2012

Azam Mohammad

Abstract excerpt

The discovery of oncogenes and tumor suppressors as a driver of cancer development has triggered the development of target-specific small molecule anticancer compounds. As exemplified by Imatinib (Gleevec), a specific inhibitor of the Chronic Myeloid Leukemia-associated BCR/ABL kinase, these agents promise impressive activity in clinical trials, with low levels of clinical toxicity. However, such therapy is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Dasatinib
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Pyridazines

Share to Thiazoles

Source

Identifiers

PMID: 22956142
DOI: 10.1007/978-1-62703-008-3_14

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents.PMID 22956142Read ↗

A method for screening and validation of resistant mutations against kinase inhibitors.Semantic proximity Read ↗

Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations.Semantic proximity Read ↗

A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein.Semantic proximity Read ↗

Tyrosine kinase inhibitors: the first decade.Semantic proximity Read ↗

Farnesyl transferase inhibitor resistance probed by target mutagenesis.Semantic proximity Read ↗

The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.Semantic proximity Read ↗

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.Semantic proximity Read ↗

CRISPR-Cas9–mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracySemantic proximity Read ↗

Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approachesSemantic proximity Read ↗

Mechanisms of drug resistance in kinasesSemantic proximity Read ↗

A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment.Semantic proximity Read ↗

Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.